Culver City-based ImmunityBio, Inc., a leading immunotherapy company, has announced that the U.S. Food and Drug ...

A new study published in AI in Precision Oncology examines the ability of large language models (LLMs) to rapidly extract ...

The US Food and Drug Administration (FDA) has approved BeiGene’s Tevimbra (tislelizumab-jsgr) along with platinum-containing ...

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...

Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of ...

Tislelizumab plus chemotherapy received FDA approval as a frontline therapy for individuals with unresectable or metastatic ...

BeiGene's Tevimbra wins FDA approval for first-line metastatic ESCC treatment, showing significant survival benefits in PD-L1 ...

Esophageal squamous cell carcinoma accounts for approximately 90% of all esophageal cancer cases. Projections estimate that ...

The researchers found that factors favoring chemoimmunotherapy included higher socioeconomic status, being uninsured, a more ...

David Zhen, MD, discussed the relevance of nivolumab in the upper gastrointestinal cancer population. In an interview with ...